Table 2. Geometric mean IgG pneumococcal antibody concentrations to individual polysaccharides at baseline and the proportion of participants with concentrations above threshold concentrations.

	30 months – 4 years						5 years+
	Control Villages			Vaccinated villages			Control Villages			Vaccinated villages
Serotypes	GM	% ≥0.35µg/ml	% >5.0µg/ml	GM	% ≥0.35µg/ml	% >5.0µg/ml	GM	% ≥0.35µg/ml	% >5.0µg/ml	GM	% ≥0.35µg/ml	% >5.0µg/ml
PCV-7
4	0.42	51.7	3.3	0.24	50.9	2.8	0.5	75.8	5.8	0.73	78.3	11.2
6B	0.36	60	3.3	0.3	63	11.1	0.95	79.5	12.7	1.53	96.1	12.8
9V	0.54	65	0	0.84	71.3	11.1	1.42	92	6	2.14	96	23
14	0.51	53.3	5	0.85	70.4	11.1	2.27	80.5	38.2	2.26	93.6	29.7
18C	0.21	45	3.3	0.26	49.1	14.8	0.62	73.2	1.7	1.13	85.9	13.6
19F	0.87	75	21.7	1.2	85.2	25	2.24	91.2	23.7	2.47	94.4	29.6
23F	0.15	40	3.3	0.26	50	13.9	0.6	73.2	11.3	0.88	73.7	16.3
Non-PCV-7
1	0.18	28.3	0	0.22	35.2	0	0.6	70.2	5.5	0.79	72.3	16.9
3	0.71	51.7	25	0.58	54.6	18.5	0.63	65	13.5	0.49	49.2	10.2
5	0.37	58.3	6.7	0.4	61.1	11.1	0.95	87.7	7.8	1.73	94.5	18.3
12F	0.31	38.3	0	0.43	43.5	6.5	0.64	65	6.7	1.13	78.1	12.1

At baseline the vaccinated and control communities were combined, and analysed according to those between 30 months and 4 years of age and those 5 years and above. The geometric means (GM) of the antibody concentrations, the proportions with concentrations that are postulated to protect against invasive pneumococcal disease (≥0.35 mg/ml) and nasopharyngeal carriage (≥5.0 µg/ml) are shown.